Clinical Trial Results:
EDEMA3: Evaluation of DX-88’s Effects in Mitigating Angioedema
A double-blind, placebo-controlled study followed by a repeat dosing phase to assess the efficacy and safety of DX-88 (recombinant plasma kallikrein inhibitor) for the treatment of acute attacks of Hereditary Angioedema
Summary
|
|
EudraCT number |
2005-003819-71 |
Trial protocol |
BE GB IT |
Global completion date |
01 Feb 2007
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
15 May 2021
|
First version publication date |
15 May 2021
|
Other versions |
|
Summary report(s) |
DX-88-14_Study Results |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.